Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
The Cryoport, Inc. (NASDAQ: CYRX) news page on Stock Titan aggregates company announcements, earnings releases, and operational updates related to its role in temperature-controlled supply chain solutions for the life sciences. Cryoport regularly issues news about its performance, infrastructure expansion, and developments across its Life Sciences Services and Life Sciences Products segments.
Recent news has highlighted quarterly financial results, including revenue from continuing operations across Life Sciences Services, BioStorage/BioServices, and Life Sciences Products. The company also reports on metrics such as the number of commercial cell and gene therapies it supports and the global clinical trials that rely on its logistics and storage capabilities.
Operational updates feature the launch and expansion of Global Supply Chain Centers, such as the facility near Paris Charles de Gaulle Airport, which is designed to provide end-to-end, temperature-controlled solutions for biopharma, animal health, and reproductive medicine. Additional news items cover product and technology introductions from MVE Biological Solutions, including dry vapor shippers and integrated condition monitoring systems powered by Tec4med, as well as the MVECloud platform for monitoring cryogenic environments.
Cryoport also publishes news on strategic actions, such as the divestiture of its CRYOPDP specialty courier business and its strategic partnership with DHL, and on quality and compliance milestones, including ISO 21973 certification for transportation of human cells for therapeutic use. Investors and industry observers can use this news feed to follow how Cryoport’s financial performance, infrastructure, and service offerings evolve over time.
Cryoport, Inc. reported Q1 2024 financial results with $54.6 million in revenue, showing a 13% decrease YoY. Despite Life Sciences Products revenue decline, Commercial Cell & Gene Therapy revenue increased 9%. Cryoport reiterated full year 2024 revenue guidance of $242-$252 million, anticipating revenue improvement. The company is investing in supporting life-saving therapies and implementing cost-saving initiatives for positive adjusted EBITDA and cash flow.
Cryoport, Inc. (Nasdaq: CYRX) will report financial results for Q1 2024 on May 7, 2024. A document reviewing financial and operational performance will be issued along with an earnings release. A conference call will address investor questions at 5:00 p.m. ET.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.